Anti-CDKS (clone W24V252) Recombinant Antibody Coupled Liposome (VS-1024-FY249) (CAT#: VS-1024-FY249)

Anti-CDKs antibody conjugated liposomes offer a promising strategy for targeted therapy in subcutaneous F9 teratocarcinoma tumors by delivering therapeutic agents directly to cancer cells while minimizing off-target effects. This targeted approach enhances the efficacy of the treatment by ensuring that the liposomes bind specifically to CDK-expressing tumor cells, potentially leading to improved therapeutic outcomes. The use of liposomes also allows for controlled release of the therapeutic agents, which can prolong the drug's action and reduce systemic toxicity. Overall, this innovative delivery system has the potential to improve the precision and effectiveness of cancer therapies, paving the way for more personalized treatment options.